Combining plasma Aβ and p-tau217 improves detection of brain amyloid in non-demented elderly
Yoshiki Niimi(University of Tokyo Hospital), Takeshi Iwatsubo(National Center of Neurology and Psychiatry), Akinori Nakamura(National Center for Geriatrics and Gerontology), Theresa A. Day(Eli Lilly (United States)), Hisatomo Kowa(Massachusetts General Hospital), Kenichiro Sato(University of Tokyo Hospital), Tadashi Tsukamoto(Broad Institute), Takeshi Ikeuchi(Niigata University), Kensaku Kasuga(Niigata University), Oskar Hansson(Eli Lilly (United States)), Michio Senda(Kyoto University), Kenji Ishii(National Institutes for Quantum Science and Technology), Michael J. Pontecorvo(Eli Lilly (United States)), Leonardo Iaccarino(University Memory and Aging Center), Samantha C. Burnham(Edith Cowan University), Ryoko Ihara(Tokyo Metropolitan Institute of Gerontology), Kazushi Suzuki(National Defense Medical College), Atsushi Iwata(National Center of Neurology and Psychiatry), Kengo Ito(National Center for Geriatrics and Gerontology), Takashi Kato(National Center for Geriatrics and Gerontology), Naoki Tomita(Tohoku University), Shorena Janelidze(Lund University), Kenji Yoshiyama(The University of Osaka)
Cited by 56
Related Papers
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
|Alzheimer s & Dementia|2011|7.1k
Lecanemab in Early Alzheimer’s Disease
|New England Journal of Medicine|2022|5k
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup
|Alzheimer s & Dementia|2024|2.3k
Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature
|Journal of Neuropathology & Experimental Neurology|2012|2.1k
High performance plasma amyloid-β biomarkers for Alzheimer’s disease
|Nature|2018|1.7k